First-in-human clinical trial of the NKT cell-stimulatory glycolipid OCH in multiple sclerosis.

Wakiro SatoDaisuke NotoManabu ArakiTomoko OkamotoYouwei LinHiromi YamaguchiRyoko Kadowaki-SagaAtsuko KimuraYukio KimuraNoriko SatoTakami IshizukaHarumasa NakamuraSachiko MiyakeTakashi Yamamura

Published in: Therapeutic advances in neurological disorders (2023)

This study has demonstrated immunomodulatory effects of the iNKT cell-stimulatory drug OCH in human. Safety profiles together with the presumed anti-inflammatory effects of oral OCH encouraged us to conduct a phase II trial.

Keyphrases

endothelial cells
multiple sclerosis
clinical trial
single cell
anti inflammatory
induced pluripotent stem cells
pluripotent stem cells
cell therapy
emergency department
open label
stem cells
bone marrow
mesenchymal stem cells
phase iii
phase ii